Anzeige
Mehr »
Montag, 12.01.2026 - Börsentäglich über 12.000 News
Kritischer Rohstoff, westliche Knappheit, hohe Gehalte: Steht hier die nächste strategische Neubewertung bevor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
191 Leser
Artikel bewerten:
(1)

The diaTribe Foundation: diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy

Expert recommendations provide crucial guidance to leverage CGM and AID during pregnancy.

SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- The diaTribe Foundation announces the publication of the first international consensus statement on the use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) during pregnancy. Published in The Lancet Diabetes & Endocrinology, the document aims to standardize care, improve outcomes, and ease the daily burden of managing type 1 (T1D), type 2 (T2D), and gestational diabetes (GDM) during pregnancy.

Managing diabetes is exceptionally challenging during pregnancy due to hormonal shifts and narrow glucose targets. As CGM and AID become standard of care in diabetes for their ability to improve management, many enter pregnancy already relying on these technologies or adopt them to help navigate this demanding time.

Despite growing use, application of technology has remained disjointed in pregnancy due to a lack of detailed clinical guidance, particularly for T2D and GDM. "Application of Continuous Glucose Monitoring and Automated Insulin Delivery Technologies for Pregnant Women with Type 1 Diabetes, Type 2 Diabetes or Gestational Diabetes Mellitus" was developed by experts across six continents to address this gap.

"It is absolutely possible to have a safe and healthy pregnancy with diabetes, and technologies can help-but these tools are often underutilized due to limited research, few devices approved for use in pregnancy, and a lack of clear guidance," said Dr. Katrien Benhalima, endocrinologist and chair of the expert author group. "Publishing this consensus is a key step to ensuring that maternal healthcare for people with diabetes continues to improve as technologies evolve."

The paper provides 14 specific recommendations, including:

  • Guidance on picking AID systems and adapting settings to meet pregnancy-specific physiological needs, including detailed charts with device-specific recommendations
  • Considerations for technology use during preconception, pregnancy, labor and delivery, and the immediate postpartum period
  • CGM time in range targets specifically for T2D and GDM, expanding upon previous standards set for T1D.

The consensus aims to support key members of the pregnancy care team who may be less familiar with diabetes technologies, including primary care and obstetrics providers, through recommendations based on the latest evidence and clinical experience. By confirming these technologies can be safely used during pregnancy, the authors also hope to increase device access and user confidence.

This initiative was led by The diaTribe Foundation and strengthened by input from 25 leading global bodies, including the American College of Obstetricians and Gynecologists, Breakthrough T1D, European Association for the Study of Diabetes, and World Organization of Family Doctors.

The diaTribe Foundation is dedicated to improving the lives of people with diabetes and advocating for action. We ensure that people have the resources and education needed to thrive with diabetes, bring people with diabetes to the conversation on regulatory issues, connect the field and the diabetes community, and change the narrative around diabetes.

Endorsing organizations:
ADJ Diabetes Brazil
Advanced Technologies & Treatments for Diabetes
American Association of Clinical Endocrinology
American College of Diabetology
American Pharmacists Association
Association of Diabetes Care & Education Specialists
Australasian Diabetes in Pregnancy Society
Australian Diabetes Society
Australian Diabetes Educators Association
Brazilian Diabetes Society
Breakthrough T1D
Centre for Chronic Disease Control (India)
Diabetes Australia
Diabetes India
European Association for the Study of Diabetes
European Board and College of Obstetrics and Gynaecology
Indian College of Obstetricians and Gynaecologists
International Association of Diabetes and Pregnancy Study Groups
International Diabetes Federation
International Federation of Gynaecology and Obstetrics
Japan Diabetes Society
Research Society for the Study of Diabetes India
Society for Obstetric Medicine India
World Organization of Family Doctors

Supported by the American College of Obstetricians and Gynecologists

Cision View original content:https://www.prnewswire.co.uk/news-releases/diatribe-convenes-international-consensus-to-guide-diabetes-technology-use-during-pregnancy-302658755.html

© 2026 PR Newswire
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.